Lau H H, Baird W M
Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.
Cancer Lett. 1992 Apr 30;63(3):229-36. doi: 10.1016/0304-3835(92)90265-w.
The mechanism of the co-carcinogenic activity of benzo[e]pyrene (BeP) was investigated by determining the effects of BeP on the binding of the carcinogen benzo[a]pyrene (BaP) to DNA in Sencar mouse epidermis. The dose of BaP used was 20 nmol/mouse, a dose which is not carcinogenic in a single application but is carcinogenic after multiple treatments such as those in the BaP-BeP co-carcinogenesis experiments described by Van Duuren and Goldschmidt (J. Natl. Cancer Inst., 56, 1237, 1976). After 3 h of exposure to [3H]BaP and BeP at BaP:BeP dose ratios of 1:3 and 1:10, [3H]BaP-DNA adducts in both BeP-treated groups were lower than in an acetone-BaP control group. After 12 and 24 h of exposure, the BaP-BeP (1:10) group contained 19% and 33% higher [3H]BaP-DNA adduct levels than the control. In the BaP-BeP (1:3) group, the amount of [3H]BaP-DNA adduct levels was higher than the control after 12 h. BeP co-treatment with either [3H]BaP-7,8-dihydrodiol or anti-[3H]BaPDE had no effect on the amount of BaPDE-DNA adducts present. These results demonstrate that the co-carcinogen BeP increases the amount of a low dose of BaP that binds to mouse epidermal DNA and indicate that the increase in BaP-DNA adducts results from increased metabolism of BaP to the proximate carcinogen BaP-7,8-dihydrodiol.
通过测定苯并[e]芘(BeP)对致癌物苯并[a]芘(BaP)与Sencar小鼠表皮DNA结合的影响,研究了BeP的促癌活性机制。所用BaP的剂量为20 nmol/小鼠,该剂量单次应用不致癌,但多次处理后具有致癌性,如Van Duuren和Goldschmidt(《美国国家癌症研究所杂志》,56, 1237, 1976)所述的BaP-BeP促癌实验。在以BaP:BeP剂量比1:3和1:10暴露于[3H]BaP和BeP 3小时后,两个BeP处理组中的[3H]BaP-DNA加合物均低于丙酮-BaP对照组。暴露12小时和24小时后,BaP-BeP(1:10)组的[3H]BaP-DNA加合物水平比对照组分别高19%和33%。在BaP-BeP(1:3)组中,暴露12小时后[3H]BaP-DNA加合物水平高于对照组。BeP与[3H]BaP-7,8-二氢二醇或抗-[3H]BaPDE共同处理对存在的BaPDE-DNA加合物数量没有影响。这些结果表明,促癌剂BeP增加了与小鼠表皮DNA结合的低剂量BaP的量,并表明BaP-DNA加合物的增加是由于BaP代谢为近端致癌物BaP-7,8-二氢二醇增加所致。